Brief: Ionis And Ono Announce Global License Agreement For Sapablursen In Polycythemia Vera
11/03/2025 22:01
March 11 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS AND ONO ANNOUNCE GLOBAL LICENSE AGREEMENT FOR SAPABLURSEN IN POLYCYTHEMIA VERA Source text: ID:nBwnhhkpa Further company coverage: IONS.O
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors